Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit at 11:00 a.m. Eastern Time on Thursday, September 26, 2024.

Neurocrine Biosciences, Inc. (NBIX) stock saw a decline, ending the day at $119.85 which represents a decrease of $-2.46 or -2.01% from the prior close of $122.31. The stock opened at $123 and touched ...

We recently compiled a list of the 10 Best Aggressive Growth Stocks to Buy According to Hedge Funds. In this article, we are ...

Neurocrine Biosciences announced that its ERUDITE Phase 2 trial for luvadaxistat failed to meet its primary endpoint in ...

During the last three months, 19 analysts shared their evaluations of Neurocrine Biosciences NBIX, revealing diverse outlooks ...

Neurocrine Biosciences’ schizophrenia program pivot has failed. | Neurocrine Biosciences’ schizophrenia program pivot has ...

Neurocrine Biosciences (NBIX) has halted development of luvadaxistat due to disappointing results from a Phase 2 study of the ...

Neurocrine (NASDAQ:NBIX) Biosciences, Inc. (NASDAQ:NBIX) reported that its Chief Corporate Affairs Officer, David W. Boyer, sold 3,461 shares of the company's common stock on September 13 ...

BMO Capital Markets analyst Evan Seigerman said luvadaxistat’s inconsistencies between mid-stage trials raise questions about ...

Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated with SchizophreniaResults Confounded by Variability in Cognition ...

During the last three months, 19 analysts shared their evaluations of Neurocrine Biosciences (NASDAQ:NBIX), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a ...